The Middle East & Africa opioids market was valued at US$ 249.22 million in 2022 and is expected to reach US$ 299.79 million by 2030; it is estimated to register a CAGR of 2.3% from 2022 to 2030.

Surging Chronic Pain Incidence Bolster Middle East & Africa Opioids Market

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis.

According to the Congressional Research Service, Americans may get more opioids at the expense of more comprehensive pain therapies. Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Middle East & Africa Opioids Market Overview

The opioids market in the Middle East & Africa is segmented into South Africa, the UAE, Saudi Arabia, and the Rest of Middle East & Africa. In the Middle East & Africa, opioids are used for pain relief, palliative care, and de-addiction of opioids. The standard of care for opioid use disorder involves treatment using medications such as methadone, buprenorphine, or naltrexone; these medications for opioid use disorder (MOUD) reduce opioid overdose deaths. In 2020, MOUD was only available as a treatment modality for opioid use disorder in Lebanon, Morocco, Iran, and the Palestinian Territories. Despite increasing economic and healthcare development in a few countries of the region, there has been a limited increase in opioid consumption in the Middle East & Africa.

Middle East & Africa Opioids Market Revenue and Forecast to 2030 (US$ Million)

Get more information on this report

Middle East & Africa Opioids Strategic Insights

Strategic insights for the Middle East & Africa Opioids provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/middle-east-and-africa-opioids-market-strategic-framework.webp

Get more information on this report

Middle East & Africa Opioids Report Scope

Report Attribute	Details
Market size in 2022	US$ 249.22 Million
Market Size by 2030	US$ 299.79 Million
Global CAGR (2022 - 2030)	2.3%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Product Immediate Release Short Acting Opioid Extended Release Long Acting Opioid By Application Pain Management Anesthesia Diarrhea Suppression Cough Suppression De-Addiction By Route of Administration Oral Injectable Transdermal Patch By Distribution Channel Hospital Pharmacies Retail Pharmacies
Regions and Countries Covered	Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Neuraxpharm Pharmaceuticals SL Endo International plc Hikma Pharmaceuticals Plc Mallinckrodt Plc Rusan Pharma Ltd Teva Pharmaceutical Industries Ltd

Get more information on this report

Middle East & Africa Opioids Regional Insights

The geographic scope of the Middle East & Africa Opioids refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

geography/middle-east-and-africa-opioids-market-geography.webp

Get more information on this report

Middle East & Africa Opioids Market Segmentation

The Middle East & Africa opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Middle East & Africa opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Middle East & Africa opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Middle East & Africa opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Middle East & Africa opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Middle East & Africa opioids market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa opioids market share in 2022.

Neuraxpharm Pharmaceuticals SL, Endo International plc, Hikma Pharmaceuticals Plc, Mallinckrodt Plc, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa opioids market.

Identical Market Reports with other Region/Countries